Kinfo
Cue Biopharma, Inc. logo

Cue Biopharma, Inc.

CUENASDAQHealthcare·US · USD
$25.57
+0.32 (+1.27%)
Prices as of October 2, 2026 · market closed

Price

Key statistics

Valuation
Market cap185.75M USD
Enterprise value171.41M USD
Trailing P/E-3.06
Forward P/E-53.27
PEG ratio-0.00
Price / sales4.93
Price / book57.85
Profitability
Gross margin0.00%
Operating margin-1113.31%
Profit margin0.00%
Return on assets-172.66%
Return on equity-1603.48%
Income (TTM)
Revenue37.66M USD
Gross profit-37.34M USD
EBITDA-97.28M USD
Net income-164.11M USD
Diluted EPS-$29.59
Rev. growth (YoY)166.70%
Balance sheet
Total cash17.41M USD
Total debt3.08M USD
Debt / equity133.20
Current ratio1.26
Book value / share$0.44
Cash flow (TTM)
Operating cash flow-50.05M USD
Levered free cash flow-33.43M USD
Shares & price
Shares outstanding5.23M
Float6.85M
Held by institutions22.83%
Beta2.46
50-day MA$28.74
200-day MA$20.11
52-week high$45.50
52-week low$4.98
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-14-1.69-24.14−1,328.40%2026-05-14-3.30-1.08+67.27%2026-03-16-2.700.30+111.11%2025-12-090.180.38+111.11%2025-11-12-2.55-2.10+17.65%
About Cue Biopharma, Inc.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision immunotherapies for allergic and autoimmune diseases. Its current portfolio centers on therapeutic biologics designed to selectively modulate disease-specific T cells and restore immune balance without broad immune suppression. The company’s lead asset, CUE-221, is an anti-IgE antibody being advanced for allergic diseases, while CUE-401 is a bifunctional IL-2 and TGF-β program designed to support Treg-mediated tolerance in autoimmune conditions. Cue Biopharma’s Immuno-STAT platform underpins its product development approach, enabling targeted immune modulation across immunological disorders. Based in Boston, Massachusetts, Cue Biopharma participates in the biotechnology sector through a pipeline aimed at addressing unmet medical needs in allergy, inflammation, and autoimmunity.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Shao-Lee Lin M.D., Ph.D.
Employees
29
Headquarters
Boston, MA, United States

Frequently asked questions about Cue Biopharma, Inc.